WO2008060574A3 - Therapeutic contact lenses with anti-fungal delivery - Google Patents

Therapeutic contact lenses with anti-fungal delivery Download PDF

Info

Publication number
WO2008060574A3
WO2008060574A3 PCT/US2007/023952 US2007023952W WO2008060574A3 WO 2008060574 A3 WO2008060574 A3 WO 2008060574A3 US 2007023952 W US2007023952 W US 2007023952W WO 2008060574 A3 WO2008060574 A3 WO 2008060574A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
polymeric hydrogel
contact lenses
recognitive polymeric
delivery system
Prior art date
Application number
PCT/US2007/023952
Other languages
French (fr)
Other versions
WO2008060574A2 (en
Inventor
Mark E Byrne
Allison Collins
Asa D Vaughan
Siddarth Venkatesh
Original Assignee
Univ Auburn
Mark E Byrne
Allison Collins
Asa D Vaughan
Siddarth Venkatesh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Auburn, Mark E Byrne, Allison Collins, Asa D Vaughan, Siddarth Venkatesh filed Critical Univ Auburn
Publication of WO2008060574A2 publication Critical patent/WO2008060574A2/en
Publication of WO2008060574A3 publication Critical patent/WO2008060574A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants

Abstract

A drug delivery system is disclosed. The drug delivery system includes a recognitive polymeric hydrogel through which a drug is delivered by contacting biological tissue. The recognitive polymeric hydrogel is formed using a bio-template, which is a drug or is structurally similar to the drug, functionalized monomers, preferably having complexing sites, and cross-linking monomers, which are copolymerized using a suitable initiator. The complexing sites of the recognitive polymeric hydrogel that is formed preferably mimic receptor sites of a target biological tissue, biological recognition, or biological mechanism of action. A system in accordance with an embodiment of the invention is a contact lens for delivering a drug through contact with an eye. In a particular embodiment of the invention, the drug is an anti-microbial, such as an anti-fungal agent for treatment of large animals, such as horses.
PCT/US2007/023952 2006-11-13 2007-11-13 Therapeutic contact lenses with anti-fungal delivery WO2008060574A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85858406P 2006-11-13 2006-11-13
US60/858,584 2006-11-13

Publications (2)

Publication Number Publication Date
WO2008060574A2 WO2008060574A2 (en) 2008-05-22
WO2008060574A3 true WO2008060574A3 (en) 2008-12-11

Family

ID=39402249

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/023952 WO2008060574A2 (en) 2006-11-13 2007-11-13 Therapeutic contact lenses with anti-fungal delivery

Country Status (1)

Country Link
WO (1) WO2008060574A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201302244A (en) 2011-07-08 2013-01-16 Univ Nat Chiao Tung Drug-carrying contact lens and manufacturing method thereof
US9827250B2 (en) 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents
US8937133B2 (en) 2012-09-25 2015-01-20 National Chiao Tung University Dissoluble PDMS-modified p(HEMA-MAA) amphiphilic copolymer and method for fabricating the same
CN115322286A (en) * 2022-07-27 2022-11-11 金陵科技学院 Contact lens for myopia prevention and control and supporting and slowly releasing atropine and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US20050208102A1 (en) * 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20060100408A1 (en) * 2002-03-11 2006-05-11 Powell P M Method for forming contact lenses comprising therapeutic agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US20060100408A1 (en) * 2002-03-11 2006-05-11 Powell P M Method for forming contact lenses comprising therapeutic agents
US20050208102A1 (en) * 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases

Also Published As

Publication number Publication date
WO2008060574A2 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
WO2006084275A3 (en) Contact drug delivery system
WO2010068281A3 (en) Contact lens drug delivery device
WO2010068862A3 (en) Zwitterionic polymers with therapeutic moieties
MX2009006146A (en) Devices and methods for ophthalmic drug delivery.
WO2010120489A3 (en) Drug delivery system and methods of use
WO2008060574A3 (en) Therapeutic contact lenses with anti-fungal delivery
MX341351B (en) Silk polymer-based adenosine release: therapeutic potential for epilepsy.
DE122012000028I1 (en) Polymer-based device with delayed release.
DK1933869T3 (en) Use of IL-23 and IL-17 Antagonists in the Treatment of Autoimmune Eye Inflammatory Disease
WO2010062523A3 (en) Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
WO2008010223A3 (en) Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders
WO2007084582A3 (en) Drug delivery treatment device
MY172901A (en) Method for making improved uv-absorbing ophthalmic lenses
WO2010011386A3 (en) Hybrid bioelectrical interface device
WO2007081396A3 (en) Initiators and crosslinkable polymeric materials
BR112012025581A2 (en) sustained release reservoir implants for intracameral drug delivery
WO2010056598A3 (en) Biodegradable alpha-2 adrenergic agonist polymeric implants
WO2010144721A3 (en) Model systems and treatment regimes for treatment of neurological disease
WO2010105130A3 (en) Opthalmic drug delivery system and applications
WO2008059501A3 (en) Use of lipid conjugates in the treatment of diseases or disorders of the eye
WO2006119128A3 (en) Vascular targeting of ocular neovascularization
WO2010061288A3 (en) Polymeric pharmaceutical dosage form in sustained release
Bedingfield et al. Top-down fabricated microplates for prolonged, intra-articular matrix metalloproteinase 13 siRNA nanocarrier delivery to reduce post-traumatic osteoarthritis
ATE437664T1 (en) ABSORBABLE BIOCOMPATIBLE COATINGS
WO2009101518A3 (en) Gellan gum based hydrogels for regenerative medicine and tissue engineering applications, its system, and processing devices

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07870885

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07870885

Country of ref document: EP

Kind code of ref document: A2